EC
DNA icon

EntryPoint Capital’s Ginkgo Bioworks DNA Stock Holding History

EntryPoint Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26,731
Closed -$262K – 738
2024
Q4 		$262K Buy
+26,731
New +$229K 0.11% 449
2024
Q2 		– Sell
-607
Closed -$28.2K – 1505
2024
Q1 		$28.2K Sell
607
-366
-38% -$18.9K 0.03% 979
2023
Q4 		$65.8K Buy
+973
New +$59.6K 0.06% 593

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

EntryPoint Capital's DNA Position: Q1 2025 in Review

EntryPoint Capital sold out of Ginkgo Bioworks (DNA) in Q1 2025, closing a stake of 26,731 shares — an estimated $262K sold.

EntryPoint Capital first reported a position in DNA in Q4 2023 and held it in 3 quarters. The position peaked at $262K in Q4 2024. 167 funds tracked by Wall St. Rank hold DNA as of Q1 2025.

  • EntryPoint Capital reported no remaining Ginkgo Bioworks position as of Q1 2025 after selling out during the quarter.
  • EntryPoint Capital sold 26,731 Ginkgo Bioworks shares in Q1 2025, an estimated $262K.
  • EntryPoint Capital first reported a position in Ginkgo Bioworks in Q4 2023 and held it in 3 quarters.
  • EntryPoint Capital's Ginkgo Bioworks position peaked at $262K in Q4 2024.
  • 167 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.